Tag: Immunotherapy

Older patients have divergent immune phenotypes at baseline that persist during immune checkpoint inhibitor therapy

Neoadjuvant PD-1 blockade with dostarlimab enables nonoperative management strategy for large proportion of patients

Predictors of longer postdiscontinuation progression-free survival include complete/partial response, longer treatment duration

Most patients include dietary consumption of allergy-triggering foods after gaining tolerance

Significantly higher rates seen for desensitization, with durable response for home-measured peanut butter ingestion versus avoidance

Clinically meaningful improvement seen in progression-free survival for transarterial chemoembolization plus lenvatinib and pembrolizumab

SCORPIO machine learning system can predict certain outcomes across diverse cancer types and health care settings

Black patients have longer time to treatment discontinuation, similar time to next treatment, slightly improved overall survival than White patients

Primary end point not met, but small subset of advanced pancreatic ductal adenocarcinoma patients showed durable responses

Benefit seen for stage III undifferentiated pleomorphic sarcoma or dedifferentiated or pleomorphic liposarcoma of the extremity and limb girdles